MabTics
MabTics
is a spin-off company established from Korea Researech Institute of Bioscience and Biotechnology (KRIBB) and pursues to make better therapeutics, especially by developing mono- and bi-specific antibodies for treating vascular diseases and cancers.
Antibody-based vessel normalization
Bispecific antibody for wAMD
Anti-thromboinflammatory antibody
Tumor-targeting antibodies
A proprietary high-diverse antibody library
EAGLES platform
MabTics
History
| 2023.07 | SI funding (1 billion KRW) |
|---|---|
| 2023.06 | Signs MOU with Curacle for development of bispecific antibody for treating wAMD |
| 2023.01 | R&D Center affiliated |
| 2022.12 | Seed funding (1.1 billion) |
| 2022.10 | Certificated as venture business |
| 2022.07 | Establishment of MabTics |